Correction to my previous post.
The acquisition by MYX for US$16M, relates only to Twyneo and Epsolay (treatment for acne and blemishes). These two products were previously marketed in the US by Galderma and this license has been terminated by mutual agreement. I have been unable to determine what the revenue for these two products is in the US. My previous post reference to US$400M relates to another product under development by SolGel which has no connection with MYX and as such MYX is not entering the R&D route that another poster has mentioned.
Perhaps a release by MYX on Tuesday will clear up this matter.
Correction to my previous post.The acquisition by MYX for...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.20 |
Change
0.150(2.97%) |
Mkt cap ! $422.4M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.24 | $5.04 | $2.929M | 567.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15203 | $5.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.22 | 631 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |